Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Bronsveld, Heleen K ^a,f   ter Braak, Bas ^b   Karlstad, Øystein ^c   Vestergaard, Peter ^d   Starup Linde, Jakob ^d,e   Bazelier, Marloes T ^f   De Bruin, Marie L ^f   de Boer, Anthonius ^f   Siezen, Christine L E ^g   van de Water, Bob ^b   van der Laan, Jan Willem ^b,g,h   Schmidt, Marjanka K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d AALBORG UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UTRECHT UNIVERSITY   (Netherlands)

^g MEDICINES EVALUATION BOARD   (Netherlands)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ANTIDIABETIC AGENT;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RISK; CARCINOGENICITY; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE DURATION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOGENICITY; NONHUMAN; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; ANIMAL; BREAST NEOPLASMS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FEMALE; MCF-7 CELL LINE; META ANALYSIS; RISK; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MCF-7 CELLS; RISK;

EID: 84939431907     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0611-2     Document Type: Article

References (83)

1. IARC. Breast cancer fact sheet. 2012.
2. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856-62.
3. Home P. Insulin therapy and cancer. Diabetes Care. 2013;36:S240-244.
4. Butler PC. Insulin glargine controversy: a tribute to the editorial team at Diabetologia. Diabetes. 2009;58:2427-8.
5. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755-65.
6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-77.
7. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-44.
8. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-54.
9. Mollentze WF. A possible link between insulin glargine and malignancy: the facts. Cardiovasc J Afr. 2009;20:216-8. discussion 218-219.
10. Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res. 2011;43:1-10.
11. Werner H, Chantelau EA. Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years. Diabetol Metabolic Syndrome. 2011;3.
12. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer. 2012;3:137-46.
13. Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8:333-48.
14. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38:485-506.
15. Du X, Zhang R, Xue Y, Li D, Cai J, Zhou S, et al. Insulin glargine and risk of cancer: a meta-analysis. Int J Biol Markers. 2012;27:e241-246.
16. Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One. 2012;7, e51814.
17. PROSPERO: http://www.crd.york.ac.uk/PROSPERO/ .
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6, e1000097.
19. The Cochrane Collaboration. Higgins JPT GS, eds.: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. 2011.
20. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, et al. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes. 2013;62:3553-60.
21. Glendorf T, Knudsen L, Stidsen CE, Hansen BF, Hegelund AC, Sorensen AR, et al. Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues. PLoS One. 2012;7, e29198.
22. Hansen BF, Glendorf T, Hegelund AC, Lundby A, Lutzen A, Slaaby R, et al. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One. 2012;7, e34274.
23. Knudsen L, Hansen BF, Jensen P, Pedersen TA, Vestergaard K, Schaffer L, et al. Agonism and antagonism at the insulin receptor. PLoS One. 2012;7, e51972.
24. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res. 2008;40:369-74.
25. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem. 2008;114:38-44.
26. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog. 1997;18:19-25.
27. Oleksiewicz MB, Bonnesen C, Hegelund AC, Lundby A, Holm GM, Jensen MB, et al. Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J Appl Toxicol. 2011;31:329-41.
28. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuille M, Tschank G, Tennagels N, et al. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One. 2012;7, e41992.
29. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, et al. Biological Effects of Insulin and Its Analogs on Cancer Cells With Different Insulin Family Receptor Expression. J Cell Physiol. 2014;229:1817.
30. Shukla A, Enzmann H, Mayer D. Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. Arch Physiol Biochem. 2009;115:119-26.
31. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer. 2009;16:429-41.
32. Staiger K, Hennige AM, Staiger H, Haering HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res. 2007;39:65-7.
33. Teng JA, Hou RL, Li DL, Yang RP, Qin J. Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res. 2011;43:519-23.
34. Ter Braak B, Siezen CL, Kannegieter N, Koedoot E, van de Water B, van der Laan JW. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. Arch Toxicol. 2014;88:953.
35. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25:41-9.
36. Gallagher EJ, Alikhani N, Tobin-Hess A, Cannata D, Tennagels N, Werner U, et al. The effect of rhIGF-1 and insulin analogue AspB10 on mammary tumour growth and progression in a mouse model of type 2 diabetes. Diabetologia. 2012;55:S289.
37. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002;21:171-9.
38. Stammberger I, Essermeant L. Insulin glargine: A reevaluation of rodent carcinogenicity findings. Int J Toxicol. 2012;31:137-42.
39. Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, Werner U. Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats. Diabetologia. 2013;56:1826-34.
40. ter Braak B, Siezen C, Speksnijder EN, Koedoot E, van Steeg H, Salvatori DC, et al. Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/(+)WAPCre mouse model. Breast Cancer Res. 2015;17:14.
41. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304-8.
42. Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Yu PC, et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care. 2014;37:1360-6.
43. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55:948-58.
44. Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, et al. Cancer risk associated with insulin Glargine among adult type 2 diabetes patients - a nationwide Cohort study. PLoS ONE. 2011;6, e21368.
45. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012;23:1193-203.
46. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard TM. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: A meta-analysis. Diabetologia. 2009;52:2507-12.
47. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases. Diabetes Care. 2013;36:294-301.
48. Ferrara A, Lewis JD, Quesenberry Jr CP, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34:923-9.
49. Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, et al. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014;37:134-43.
50. Gu YJ, Wang CF, Zheng Y, Hou XH, Mo YF, Yu WH, et al. Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai. Plos One. 2013;8, e53411.
51. Habel LA, Danforth KN, Quesenberry CP, Capra A, Van Den Eeden SK, Weiss NS, et al. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patientswith diabetes. Diabetes Care. 2013;36:3953-60.
52. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499-506.
53. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782.
54. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf. 2007;16:485-92.
55. Kostev K. Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia. 2012;55:1554-5.
56. Lind M, Fahlen M, Eliasson B, Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes. 2012;6:53-9.
57. Ljung R, Talback M, Haglund B, Jonasson JM, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation. Acta Oncol. 2011;50:685-93.
58. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997-2003.
59. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011;34:1965-71.
60. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953-62.
61. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. European J Cancer Prev. 2014;23:134-40.
62. Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012;23:1785-95.
63. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia. 2009;52:1971-3.
64. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55:51-62.
65. Sturmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, et al. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care. 2013;36:3517-25.
66. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011;54:2254-62.
67. Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clinical drug Invest. 2013;33:621-31.
68. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One. 2010;5, e9540.
69. Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin. 2003;19:34-40.
70. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35:2626-30.
71. Jorgensen L, Dideriksen L, Drejer K. Carcinogenic effect of the human insulin analog b10 asp in female rats. In: Diabetologia: 1992. 175 Fifth ave, New York, NY 10010: Springer Verlag; 1992. p. A3-3.
72. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19:R225-241.
73. Van Oosterhout JP, Van der Laan JW, De Waal EJ, Olejniczak K, Hilgenfeld M, Schmidt V, et al. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol. 1997;25:6-17.
74. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012;135:639-46.
75. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28.
76. Besic N, Satej N. Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma. BMC Res Notes. 2013;6:416.
77. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29:40-6.
78. Luo J, Virnig B, Hendryx M, Wen S, Chelebowski R, Chen C, et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res Treat. 2014;148:153-62.
79. Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat. 2013;137:807-16.
80. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EAM, Moller H, et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55:1619-32.
81. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;109:389-95.
82. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98:668-77.
83. Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One. 2014;9:e93132.